{"nctId":"NCT02186171","briefTitle":"A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis","startDateStruct":{"date":"2014-06-16","type":"ACTUAL"},"conditions":["Osteoporosis in Men"],"count":245,"armGroups":[{"label":"Romosozumab","type":"EXPERIMENTAL","interventionNames":["Biological: Romosozumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Romosozumab","otherNames":["AMG 785","EVENITY™"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age\n* Must have a BMD T score ≤ -2.50 at the spine or hip, or BMD T score ≤ -1.50 at the spine or hip and a history of fragility nonvertebral fracture or vertebral fracture.\n\nExclusion Criteria:\n\n* A BMD T score ≤ -3.50 at the hip,\n* History of hip fracture\n* Severe metabolic bone diseases\n* Significant laboratory abnormalities\n* Recent treatment with agents affecting bone metabolism","healthyVolunteers":false,"sex":"MALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12","description":"Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.5"},{"groupId":"OG001","value":"12.1","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in BMD at the Total Hip at Month 12","description":"Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.3"},{"groupId":"OG001","value":"2.5","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in BMD at the Femoral Neck at Month 12","description":"Femoral neck bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.4"},{"groupId":"OG001","value":"2.2","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine BMD at Month 6","description":"Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.4"},{"groupId":"OG001","value":"9.0","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in BMD at the Total Hip at Month 6","description":"Bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.2"},{"groupId":"OG001","value":"1.6","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in BMD at the Femoral Neck at Month 6","description":"Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"1.2","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":81},"commonTop":["Nasopharyngitis","Back pain","Hypertension","Arthralgia","Headache"]}}}